Precision-oncology biotech developing targeted small molecules for prostate cancer and EGFR/HER2-mutant lung cancer.
Precision-oncology biotech developing targeted small molecules for prostate cancer and EGFR/HER2-mutant lung cancer.
Has no approved product, so it earns nothing from sales and pays for trials by selling shares and from cash raised before. Its two lead drugs target prostate cancer and lung cancer with specific gene changes; partnering with a larger drugmaker is the usual route to commercialise later.
Moat: none (IP / patents). Pre-commercial; competes with larger, better-funded oncology programs at bigger companies.
Headquarters: South San Francisco, California, US · Founded: 2017 · Employees: 104
Size Oric Pharmaceuticals (ORIC) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $795M, the 2372nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.65 on 18 Nov 2026.
Performance Over six months the shares fell 9.0%, against -5.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 19 in its peer set.
Capital Return on invested capital runs 177.0 points below its cost of capital (11.2% WACC).
Short interest Short interest is 10.3% of the free float (30 Oct 2026).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$1.13M | -$1.22M | -$1.11M | -$1.03M | -$966,000 |
| EBITDA | -$170M | -$142M | -$142M | -$110M | -$85.8M |
| Net income | -$156M | -$129M | -$128M | -$101M | -$89.1M |
| Free cash flow | -$130M | -$114M | -$114M | -$86.8M | -$77.6M |
| Capital expenditure | $692,000 | $712,000 | $1.19M | $849,000 | $2.08M |
| Total debt | $3.35M | $7.44M | $9.36M | $10.2M | $12.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Oric Pharmaceuticals ORIC | $795M | -9% | n/a | n/a | n/a | n/a |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 6.9× | 3.7% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 3.3× | -4.3% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 5.0× | 14.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ORIC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -44.5% | -0.9% | lowest of 19 |
| 6-month return | -9.0% | -5.0% | 8th lowest of 19 |
| Distance from 52-week high | -47.9% | -31.2% | 4th lowest of 19 |
| ROIC minus cost of capital | -177.0 pp | -0.5 pp | lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 4.1× | 16.3% | -8.7% |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 1.8× | 6.6% | +17.7% |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 2.6× | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 2.5× | 1.5% | +22.1% |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 3.1× | 13.9% | +27.7% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | 789.4× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | 3.1× | -2.5% | +2.6% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 2.3× | -2.6% | +20.3% |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 1.6× | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | 0.3× | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 1.8× | 4.6% | +22.5% |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | 6.7× | 33.9% | +10.1% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | 0.9× | -3.8% | -0.8% |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | 7.0× | 27.7% | -39.5% |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | 6.5× | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | 13.8× | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | 16.7× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | 2.4× | 0.3% | +0.5% |